Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm.
BACKGROUND
Ergosta-4,6,8(14),22-tetraen-3-one (ergone) has been proven to prevent the progression of renal injury and the subsequent renal fibrosis. We investigated the therapeutic effects and mechanism of ergone on a chronic renal failure model of rats induced by adenine.


METHODS
A serum metabonomic method based on the UPLC Q-TOF/MS was undertaken to explore the excretion pattern of low molecular mass metabolites.


RESULTS
Coupled with blood biochemistry and kidney histopathology results, the significant difference in metabolic profiling between adenine-induced chronic renal failure group and the ergone treated group by using pattern recognition analysis indicated that changes in global serum metabolites occurred. Some significantly changed metabolites like lysophosphatidylcholines, adenine, dopamine, creatinine, aspartic acid and phenylalanine have been found and identified. These biochemical changes in serum metabolites are related to the perturbations of amino acid metabolism and lecithin metabolism, which may be helpful to further understand the chronic renal failure and therapeutic mechanisms of ergone.


CONCLUSIONS
The work shows that the metabonomic method is a valuable tool for studying the essence of chronic kidney disease and therapeutic effect mechanism of preclinical or clinical drug.
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, the College of Life Sciences, Northwest University, No.229 Taibai North Road, Xi'an, Shaanxi 710069, China. zyy@nwu.edu.cn
Ying-Yong
YY
Zhao
Xian-Long
XL
Cheng
Ji-Hong
JH
Cui
Xing-Rong
XR
Yan
Feng
F
Wei
Xu
X
Bai
Rui-Chao
RC
Lin
D000225:Adenine / Q000009:adverse effects / Q000097:blood; D000818:Animals; D001224:Aspartic Acid / Q000097:blood; D002783:Cholestenones / Q000008:administration & dosage*; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000097:blood; D004298:Dopamine / Q000097:blood; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control*; D050356:Lipid Metabolism; D008244:Lysophosphatidylcholines / Q000097:blood; D008297:Male; D055432:Metabolomics; D010649:Phenylalanine / Q000097:blood; D025341:Principal Component Analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D002783:Cholestenones; D008244:Lysophosphatidylcholines; D001224:Aspartic Acid; D010649:Phenylalanine; D003404:Creatinine; D000225:Adenine; C015860:ergosta-4,6,8(14),22-tetraen-3-one; D004298:Dopamine